Obesity-hypertension: Emerging concepts in pathophysiology and treatment

American Journal of the Medical Sciences

Volumn 334, Issue 1, 2007, Pages 23-30

  Mathew, Boban ^a   Patel, Sanjeev B ^a   Reams, Garry P ^b   Freeman, Ronald H ^b   Spear, Robert M ^a   Villarreal, Daniel ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b NONE

Author keywords

Cardiac hypertrophy; Endocannabinoid 1 receptor; Leptin; Natriuresis

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; LEPTIN; MOXONIDINE; NITRIC OXIDE; NORADRENALIN; RIMONABANT; SEROTONIN; SIBUTRAMINE; SODIUM; TETRAHYDROLIPSTATIN;

ADIPOCYTE; ADRENERGIC SYSTEM; ARTERIAL PRESSURE; BORBORYGMI; BROWN ADIPOSE TISSUE; CALORIC INTAKE; CLINICAL TRIAL; ENERGY BALANCE; ENERGY EXPENDITURE; EXERCISE; FLATULENCE; FLUID BALANCE; GASTROINTESTINAL SYMPTOM; HEMODYNAMICS; HUMAN; HYPERLEPTINEMIA; HYPERTENSION; HYPOTHALAMUS; INCIDENCE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; MORBIDITY; MORTALITY; MOUSE STRAIN; MUSCLE CRAMP; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; REVIEW; SEROTONIN UPTAKE; SODIUM BALANCE; SODIUM EXCRETION; SPONTANEOUSLY HYPERTENSIVE RAT; SPRAGUE DAWLEY RAT; THROMBOCYTE AGGREGATION; VASODILATATION; WEIGHT CONTROL;

EID: 34447559480     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3180959e4e     Document Type: Article

References (58)

1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
2. Hall JE, Crook ED, Jones DW, et al. Mechanisms of obesity-associated cardiovascular and renal disease. Am J Sci 2002;324:127-37.
3. Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:235-51.
4. Hutley L, Prins J. Fat as an endocrine organ: relationship to the metabolic syndrome. Am J Med Sci 2005;330:280-9.
5. Guha PK, Villarreal D, Reams GP, et al. Role of leptin in the regulation of body fluid volume and pressures. Am J Ther 2003;10:211-8.
6. Sharma V, McNeill J. The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology. Curr Vasc Pharmacol 2005;3:169-80.
7. Beltowski J. Role of leptin in blood pressure regulation and arterial hypertension. J Hypertens 2006;24:789-901.
8. Haynes WG, Morgan DA, Walsh SA, et al. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997;100:270-8.
9. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes 1997;46:2040-3.
10. Villarreal D, Reams G, Freeman RH, et al. Renal effects of leptin in normotensive, hypertensive and obese rats. Am J of Physiol 1998;275:R2056-60.
11. Rahmouni K, Correia LG, Haynes W, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005;45:9-14.
12. Lembo L, Vecchione C, Fratta L. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes 2000;49:293-7.
13. Vecchione C, Maffei A, Colella S, et al. Leptin effect on endothelial nitric oxide is mediated through Akt-endothelial nitric oxide synthase phosphorylation pathway. Diabetes 2002;51:168-73.
14. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999;48:903-8.
15. Mitchell JL, Morgan DA, Correia ML, et al. Does leptin stimulate nitric oxide to oppose the effects of sympathetic activation? Hypertension 2001;38:1081-6.
16. Gardiner SM, Kemp PA, March JE, et al. Regional hemodynamic effects of recombinant murine or human leptin in conscious rats. Br J Pharmacol 2000;130:805-10.
17. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 endothelial cells in vitro. Circ Res 2002;90:711-8.
18. Bouloumine A, Marumo T, Lofanton M, et al. Leptin induces oxidative stress in human endothelial cells. FASEB J 1999;13:1231-8.
19. Correia MI, Haynes WG, Rahmouni K. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002;51:439-42.
20. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998;31:409-14.
21. Kuo JJ, Jones O, Hall J. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 2001;1:37:670-6.
22. Aizawa-Abe M, Ogawa Y, Masuzaki H, et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000;105:1243-52.
23. Serradeil-Le G, Raufaste D, Brossard G, et al. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett 1997;404:185-91.
24. Bado A, Levasseur S, Attoub S, et al. The stomach is a source of leptin. Nature 1998;394:790-3.
25. Jackson EK, Li P. Human leptin has natriuretic activity in the rat. Am J Physiol 1997;272:333-8.
26. Villarreal D, Reams G, Freeman RH. Effects of renal denervation on the sodium excretory action of leptin in hypertensive rats. Kidney Int 2000;58:989-94.
27. +-ATPase activity in the rat-impaired effect in dietary-induced obesity. Med Sci Monit 2002;8:BR221-9.
28. Villarreal D, Reams G, Samar H, et al. Effects of chronic nitric oxide inhibition on the renal excretory response to leptin. Obes Res 2004;12:1006-10.
29. Villarreal D, Reams G, Samar H. Leptin blockade attenuates sodium excretion in saline-loaded normotensive rats. Mol Cell Biochem 2006;283:153-7.
30. Dobrian AD, Schriver SD, Lynch T, et al. Effect of salt on hypertension and oxidative stress in rat model on diet-induced obesity. Am J Physiol 2003;285:F619-28.
31. Emilsson V, Liu YL, Cawthorne MA, et al. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997;46:313-36.
32. Konstantinides S, Schafer K, Koschnick S, et al. Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity. J Clin Invest 2001;108:1533-40.
33. Sierra-Honigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor, Science 1998;281:1683-6.
34. Umemoto Y, Tsuji K, Yang FC, et al. Leptin stimulates the proliferation of murine myelocytic and primitive hematopoietic progenitor cells. Blood 1997;90:3438-43.
35. Paolisso G, Tangliamonte MR, Galderisi M, et al. Plasma leptin level is associated with myocardial wall thickness in hypertensive insulin resistant men. Hypertension 1999;34:1047-52.
36. Luo J-D, Zhang G-S, Chen M-S, et al. Leptin and cardiovascular diseases, Drug News Perspect 2005;18:427-31.
37. Rajapurohitam V, Gan XT, Kirshenbaum LA, et al. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res 2003;93:277-9.
38. Barouch LA, Berkowitz DE, Harrison RW, et al. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation 2003;108:754-9.
39. Tajmir P, Ceddia RB, Li RK, et al. Leptin increases cardiomyocyte hyperplasia via extracellular signal-regulated kinase-and phosphatidylinositol 3-kinase-dependent signaling pathways; Endocrinology 2004;145:1550-5.
40. Atkinson LL, Fischer MA, Lopaschuk GD. Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylasemalonyl-CoA axis. J Biol Chem 2002;277:29424-30.
41. Nickola M, Wold L, Colligan P, et al. Leptin attenuates cardiac contraction in rat ventricular myocytes: role of NO hypertension 2000;36:501-5.
42. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996;79:363-80.
43. Wold LE, Relling DP, Duan J, et al. Abrogated leptin-induced cardiac contractile response in ventricular myocytes under spontaneous hypertension: role of JAK/STAT pathway. Hypertension 2002;39:69-74.
44. Tritos NA, Manning WJ, Danias PG, et al. Role of leptin in the development of cardiac hypertrophy in experimental animals and humans. Circulation 2004;109:e67.
45. Schulze PC, Kratzsch J, Linke A, et al. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur J Heart Fail 2003;5:33-40.
46. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never smoking overweight US white women aged 40-64. Am J Epidemiol 1995;141:1128-41.
47. Stevens VJ, Obarzanek E, Cook NR, et al. Long term weight loss and changes in blood pressure: results of the trials of hypertension prevention, phase II. Ann Intern Med 2001;134:1-11.
48. Hafidh S, Senkottaiyan N, Villareal D, et al. Management of metabolic syndrome. Am J Med Sci 2005;330:343-50.
49. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines: revision 2000. Circulation 2000;102:2284-99.
50. Liebel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995;332:621-8.
51. Snow V, Barry P, Fitterman N, et al. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005;142:525-31.
52. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005;142:532-46.
53. Van Gaal LF, Peiffer F. New approaches for the management of patients with multiple cardiometabolic risk factors. J Endocrinol Invest 2006;29:83-9.
54. Curioni C, Andre C. Rimonabant for overweight or obesity. Cochrane based database systematic Review 2006;CD 006162.
55. Sharma AM, Pischon T, Engeli S, et al. Choice of drug treatment for obesity-related hypertension: where is the evidence? J Hypertens 2001;19:667-74.
56. Sanjuliani AF, deAbreu VG, Francischetti EA. Selective Imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006;60:621-9.
57. Amador N, Guizar J-M, Malacara J-M, et al. Sympathetic activity and response to ACE inhibitor (Enalapril) in normotensive obese and nonobese subjects, Arch Med Res 2004;35: 54-8.
58. Forgari R, Derosa G, Zoppi A, et al. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 2005;28:209-14.